Carnegie acted as sole global co-ordinator and bookrunner in the directed share issue of 6,537,973 new shares at a subscription price of SEK 22.50 per share. Intervacc´s main area is to develop modern sub-unit vaccines against economically important bacterial infections, within animal health. June 2020.
Healthcare
Directed share issue in Intervacc AB — SEK 147 million
June 2020